Orexo resubmits IZIPRY NDA to FDA for opioid overdose treatment

Bitget2026/09/29 13:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Orexo completed its FDA resubmission of the IZIPRY (naloxone nasal powder) NDA on Sept. 29, 2026.
Filing aims to address deficiencies cited in the FDA’s July 2024 complete response letter.
FDA acceptance decision and an updated review timeline are expected in the coming weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Orexo resubmits IZIPRY NDA to FDA for opioid overdose treatment

You may also like

Crypto prices